

FOR IMMEDIATE RELEASE

Company Name Kyowa Kirin Co., Ltd.
Representative Abdul Mullick, President and COO
(Code No. 4151, Prime Market of TSE)
Inquiries Hiroki Nakamura, Executive Vice President,
Corporate Communications Department
Media Contact: +81-3-5205-7205
Investor Contact: +81-3-5205-7206

Announcement regarding the Dissolution and Liquidation of a Specified Subsidiary

Tokyo, Japan, July 11, 2025 - Kyowa Kirin Co., Ltd. (President and COO: Abdul Mullick, "Kyowa Kirin") hereby announced that our consolidated subsidiary, Kyowa Kirin International plc, which holds 100% of the shares of Orchard Therapeutics Limited ("ORHD"), has resolved to proceed with the dissolution and liquidation of ORHD.

1. Purpose of the Change

As announced in the "Notice regarding Completion of Share Acquisition of Orchard Therapeutics plc (overview of the acquisition)" on January 25, 2024, Kyowa Kirin has acquired 100% of issued shares of Orchard Therapeutics plc (currently Orchard Therapeutics Limited). In order to enhance management efficiency, the oversight and management functions for ORHD subsidiary companies, which were previously handled by ORHD, will be transferred to Orchard Therapeutics (Europe) Limited – a company in which ORHD holds all the shares – and ORHD will be liquidated. Since Kyowa Kirin International plc. will hold 100% of the issued shares of Orchard Therapeutics (Europe) Limited, there will be no changes to the management structure.

2. Outline of the Specified Subsidiary to be liquidated

(1)	Name	Orchard Therapeutics Limited	
(2)	Location	245 Hammersmith Road, 3rd Floor London W6 8PW United Kingdom	
(3)	Job title and name of representative	Bobby Gaspar, Chief Executive Officer	
(4)	Description of business	Oversight and management of subsidiary companies;	
(5)	Equity capital	USD 29,569,322.69	
(6)	Date of establishment	August 1, 2018	
(7)	Major Shareholders and Shareholding Ratio	Kyowa Kirin International plc. 100%	
(8)	Relationship between the Company and the party mentioned	Capital relationship	Kyowa Kirin's wholly-owned subsidiary, Kyowa Kirin International plc. owns 100% of the shares.
		Personal relationship	Two directors and one executive officer from Kyowa Kirin serve as directors of the company.
		Business relationship	Loan of funds

Operating results and financial condition for the latest three years (in millions of USD)				
(9)	Fiscal Year	FY2022	FY2023	FY2024
	Net Assets	45.9	369.6	305.1
	Total Assets	80.1	453.7	372.5
	Revenues	-	-	-
	Profit	(136.3)	275.6	(65.9)

3. Schedule

In accordance with applicable local laws, we will initiate the dissolution and liquidation proceedings. However, the specific timing for the completion of the liquidation remains undetermined at this time.

4. Outlook

The impact of this dissolution and liquidation on our consolidated financial performance is expected to be minimal.

End